

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT3827963

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
ANDRES GAGETE MATEOS	04/05/2016
LUC MARTI CLAUZEL	04/04/2016
DAMIA TORMO CARULLA	04/05/2016
JULIO CASTRO PALOMINO	04/04/2016
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	ARTAX BIOPHARMA INC.
<b>Street Address:</b>	1 BROADWAY, 14TH FLOOR
<b>City:</b>	CAMBRIDGE
<b>State/Country:</b>	MASSACHUSETTS
<b>Postal Code:</b>	02142
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	15029042
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(248)440-7300
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	248-430-5768
<b>Email:</b>	patdocketing@bluefilamentlaw.com
<b>Correspondent Name:</b>	BLUE FILAMENT LAW
<b>Address Line 1:</b>	450 NORTH OLD WOODWARD
<b>Address Line 2:</b>	FIRST FLOOR
<b>Address Line 4:</b>	BIRMINGHAM, MICHIGAN 48009
<b>ATTORNEY DOCKET NUMBER:</b>	CHOI-156US-15009
<b>NAME OF SUBMITTER:</b>	AVERY N. GOLDSTEIN, PH.D.
<b>SIGNATURE:</b>	/Avery N. Goldstein, Ph.D./
<b>DATE SIGNED:</b>	04/13/2016
This document serves as an Oath/Declaration (37 CFR 1.63).	
<b>Total Attachments: 3</b>	

source=CHOI-156US-Signed-Assignment-By-Inventors#page1.tif

source=CHOI-156US-Signed-Assignment-By-Inventors#page2.tif

source=CHOI-156US-Signed-Assignment-By-Inventors#page3.tif

## ASSIGNMENT BY INVENTORS

**THIS ASSIGNMENT**, made this 4th day of April, 2016, by Andrés Gagete Mateos, Luc Marti Clauzel, Damiá Tormo Carulla and Julio Castro Palomino (hereinafter referred to as Assignors), the first three Assignors routinely receiving mail at 1 Broadway, 14<sup>th</sup> Floor, Cambridge, Massachusetts 02142, UNITED STATES OF AMERICA, and the fourth Assignor routinely receiving mail at Palobiofarma S.L., Ernest Lluch 32, E-08302 Barcelona, SPAIN; and

**WHEREAS**, Assignors have invented certain new and useful improvements in CHROMENE DERIVATIVES SUBSTITUTED BY ALKOXIDE AS INHIBITORS OF THE TCR-NCK INTERACTION, set forth in a Patent Application for which an International Application was filed on October 20, 2014, Serial No. PCT/IB2014/002171, designating the United States and filed on April 13, 2016, 2016 under U.S. Serial No. 15/029,042, and to which priority benefit is claimed for Spanish Serial No. p 201331542, filed on October 18, 2013; and

**WHEREAS**, ARTAX BIOPHARMA INC., a corporation organized under and pursuant to the laws of the UNITED STATES OF AMERICA, having its principal place of business at 1 Broadway, 14<sup>th</sup> Floor, Cambridge, Massachusetts 02142, UNITED STATES OF AMERICA; (hereinafter referred to as Assignee), is desirous of acquiring the entire right, title and interest in and to said inventions and said Application for Letters Patent of the United States, and in and to any Letters Patent of the United States to be obtained therefore and thereon.

**NOW, THEREFORE**, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignors have sold, assigned, transferred and set over, and by these presents do sell, assign, transfer and set over, unto Assignee, its successors, legal representatives and assigns, the entire right, title and interest in and to the above-mentioned inventions and application for Letters Patent, and in and to any and all direct and indirect divisions, continuations and continuations-in-part of said application, and any and all Letters Patent in the United States and all foreign countries which may be granted therefor and thereon, and reissues, reexaminations and extensions of said Letters Patent, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and

enjoyed by Assignee, for its own use and benefit and the use and benefit of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent may be granted and/or extended, as fully and entirely as the same would have been held and enjoyed by Assignors, had this sale and assignment not been made; and including the right to recover for past, present and future infringement and damages.

**AND** for the same consideration, Assignors hereby represent and warrant to Assignee, its successors, legal representatives and assigns, that, at the time of execution and delivery of these presents, except for any rights, titles and/or interests that have arisen to Assignee under law or that have already been transferred to Assignee, Assignors are the sole and lawful owners of the entire right, title and interest in and to the said inventions and application for Letters Patent above-mentioned, and that the same are unencumbered and that Assignors have good and full right and lawful authority to sell and convey the same in the manner herein set forth.

**AND** for the same consideration, Assignors hereby covenant and agree to and with Assignee, its successors, legal representatives and assigns, that Assignors will sign all papers and documents, take all lawful oaths and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of any Letters Patent and applications for Letters Patent for said inventions, without charge to Assignee, its successors, legal representatives and assigns, whenever counsel of Assignee, or counsel of its successors, legal representatives and assigns, shall advise: that any proceeding in connection with said inventions, or said Patent application for Letters Patent, or any proceeding in connection with any Letters Patent or applications for Letters Patent for said inventions in any country, including but not limited to interference proceedings, is lawful and desirable; or, that any division, continuation or continuation-in-part of any application for Letters Patent, or any reissue, reexamination or extension of any Letters Patent, to be obtained thereon, is lawful and desirable.

**AND** Assignors hereby request the Commissioner of Patent and Trademarks to issue said Letters Patent of the United States to Assignee, as Assignee of said inventions and the Letters Patent to be issued thereon, for the sole use and benefit of Assignee, its successors, legal representatives and assigns.

AND Assignors hereby grant the following individuals the power to insert on this Assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document:





Avery N. Goldstein, Ph.D.

BLUE FILAMENT LAW PLLC

All practitioners at Customer Number 13173

AND Assignors acknowledge an obligation of assignment of this invention to Assignee at the time the invention was made.

The above-identified application was made or authorized to be made by me. I believe that I am the original inventor or an original joint inventor of a claimed invention in the application. I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

Date:	<u>5-4-2016</u>	Signature:	
			_____ Andrés Gagete Mateos
Date:	<u>04-04-2016</u>	Signature:	
			_____ Luc Marti Clauzel
Date:	<u>05-04-2016</u>	Signature:	
			_____ Damiá Tormo Carulla
Date:	<u>09/09/2016</u>	Signature:	
			_____ Julio Castro Palomino